Profile

Procarta Biosystems

Procarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).

Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology

Website www.procartabio.com

Associated Team Members

Relevant News

UK biotech bags €1.5m grant for new antibiotic class

Procarta Biosystems has picked up €1.5m in funding to help develop a new antibiotic...

read more

Drugs For Escherichia Coli Infections Market Analysis by Manufacturers, region,...

Atterx Bio Therapeutics,GlycoVaxyn,Melinta Therapeutics,Soligenix,Evolva,Nymox Pharmaceutical,Syntiron,Procarta Biosystems,Phico Therapeutics ...

read more

Novo Holdings invests in three more AMR biotechs

Finally, UK-based Procarta Biosystems has received €1.5 million from the Fund. Procarta is developing...

read more

Antibiotics and the Gut Microbiome

A study recently published in Nature Communications (30 June) has shown that even small...

read more

ICNN 2015 : 17th International Conference on Nanotechnology and Nanomedicine

Clara Franch de la Cal will be representing Procarta Biosystems at the 17th International Conference...

read more

Procarta Biosystems joins BEAM Alliance

The BEAM Alliance is working “to improve the regulatory, investment, and commercial environments in...

read more

More Companies in Medical / Biotechnology